Proudly recognized by global quality standards. These certifications demonstrate our commitment to safety, excellence, and customer trust.
Recent Posts
-
Retlirafusp Alfa: A New Approach to Cancer Immunotherapy September 4, 2026 -
Izalontamab Brengitecan (Iza-Bren) in 2026: Development, Clinical Progress and Market Outlook August 27, 2026 -
NMPA Approves Ivonescimab in Combination With Chemotherapy for First-Line Squamous NSCLC August 18, 2026 -
Recombinant Crisantaspase and Its Role in Leukemia and Lymphoblastic Lymphoma Treatment August 12, 2026 -
Which Documents Are Needed for a Named Patient Program? August 6, 2026


